Natera (NASDAQ:NTRA) Sets New 52-Week High – Here’s Why

Posted by Brian Himes on Jul 1st, 2026

Natera, Inc. (NASDAQ:NTRA – Get Free Report) shares hit a new 52-week high on Wednesday . The stock traded as high as $275.24 and last traded at $271.45, with a volume of 1371550 shares. The stock had previously closed at $272.31.

Wall Street Analysts Forecast Growth

NTRA has been the topic of a number of research reports. Royal Bank Of Canada started coverage on shares of Natera in a report on Thursday, June 11th. They set an “outperform” rating and a $275.00 target price on the stock. Morgan Stanley dropped their price target on shares of Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a research note on Tuesday, March 3rd. UBS Group set a $260.00 price objective on Natera in a research report on Wednesday, June 24th. Wolfe Research began coverage on Natera in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 price objective on the stock. Finally, Robert W. Baird set a $265.00 target price on Natera in a report on Friday, May 8th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $260.33.

Read Our Latest Analysis on NTRA

Natera Price Performance

The stock’s 50 day moving average is $215.51 and its two-hundred day moving average is $216.23. The stock has a market capitalization of $38.88 billion, a PE ratio of -166.53 and a beta of 1.56.

Insider Activity at Natera

In other Natera news, CEO Steven Leonard Chapman sold 41,124 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $221.03, for a total value of $9,089,637.72. Following the sale, the chief executive officer directly owned 108,743 shares of the company’s stock, valued at approximately $24,035,465.29. This represents a 27.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gail Boxer Marcus sold 11,000 shares of the firm’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the completion of the sale, the director owned 6,183 shares in the company, valued at $1,343,009.43. The trade was a 64.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 175,872 shares of company stock worth $38,808,996 over the last ninety days. 5.05% of the stock is currently owned by insiders.

Institutional Trading of Natera

Hedge funds and other institutional investors have recently bought and sold shares of the business. Reflection Asset Management purchased a new stake in Natera during the 4th quarter worth about $29,000. Palladiem LLC acquired a new position in shares of Natera during the 4th quarter worth about $31,000. Horizon Investments LLC purchased a new position in shares of Natera in the 3rd quarter valued at about $32,000. International Assets Investment Management LLC increased its holdings in shares of Natera by 132.9% in the 1st quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 97 shares during the last quarter. Finally, Bank of Jackson Hole Trust increased its holdings in shares of Natera by 103.8% in the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 83 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Company Profile

(Get Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.